Talecris Biotherapeutics Holdings Corp. (TLCR) is a publicly traded company in the Unknown sector. Across all available filings, 22 corporate insiders have executed 140 transactions totaling $642.7M, demonstrating a bearish sentiment with -$642.7M in net insider flow. The most recent transaction on Jun 1, 2011 involved a transaction of 15,707,155 shares valued at $0.
No significant insider buying has been recorded for TLCR in the recent period.
No significant insider selling has been recorded for TLCR in the recent period.
Based on recent SEC filings, insider sentiment for TLCR is bearish with an Insider Alignment Score of 0/100 and a net flow of -$642.7M. Insiders are reducing their positions, though this can be driven by factors unrelated to company outlook.
Insider trading at Talecris Biotherapeutics Holdings Corp. (TLCR) refers to stock transactions made by corporate insiders—executives, directors, and beneficial owners holding more than 10% of the company's shares. These individuals have access to material non-public information and are required by law to report their trades to the SEC within two business days. Currently, 22 insiders are actively trading TLCR stock, having executed 140 transactions in the past 90 days. The most active insider is Stephen Feinberg (Executive), who has made 1 transactions totaling $485.9M.
Get notified when executives and directors at TLCR file new Form 4 transactions
Date | Insider | Title | Type | Shares | Price | Value | Flags |
|---|---|---|---|---|---|---|---|
| Jun 1, 2011 | Lp Ampersand 2001 | Executive | Tender | 15,707,155 | $N/A | $0 | |
| Jun 1, 2011 | E. Abelson Joel | Executive | Disposition | 8,810 | $N/A | $0 | |
| Jun 1, 2011 | N. Clark Paul | Executive | Disposition | 12,715 | $N/A | $0 | |
| Jun 1, 2011 | R. Engle James | Executive | Disposition | 3,655 | $N/A | $0 | |
| Jun 1, 2011 | Brett Ingersoll W. | Executive | Disposition | 3,019 | $N/A | $0 | |
| Jun 1, 2011 | T. Lenehan James | Executive | Disposition | 139,891 | $N/A | $0 | |
| Jun 1, 2011 | J. Martin Kenneth | Executive | Disposition | 12,715 | $N/A | $0 | |
| Jun 1, 2011 | F. Mayer Steven | Executive | Disposition | 3,019 | $N/A | $0 | |
| Jun 1, 2011 | J. Mitchell Dean | Executive | Disposition | 3,019 | $N/A | $0 | |
| Jun 1, 2011 | E. Waeger Ruedi | Executive | Disposition | 63,587 | $N/A | $0 | |
| Jun 1, 2011 | F. Gaither John Jr | Executive | Disposition | 23,072 | $N/A | $0 | |
| Jun 1, 2011 | M. Hanson John | Executive | Disposition | 89,331 | $N/A | $0 | |
| Jun 1, 2011 | D. Heerdt Kari | Executive | Disposition | 5,484 | $N/A | $0 | |
| Jun 1, 2011 | J. Kuhn Mary | Executive | Disposition | 63,779 | $N/A | $0 | |
| Jun 1, 2011 | J. Lynch Thomas | Executive | Disposition | 3,655 | $N/A | $0 |
| TYPE | COUNT | VALUE | % |
|---|---|---|---|
Sale(S) | 31 | $642.7M | 97.7% |
Exercise(M) | 32 | $8.0M | 1.2% |
Payment(F) | 23 | $7.3M | 1.1% |
Tender(U) | 1 | $0 | 0.0% |
Disposition(D) | 21 | $0 | 0.0% |
Award(A) | 32 | $0 | 0.0% |
Insider selling pressure at Talecris Biotherapeutics Holdings Corp. has increased, with 22 insiders executing 140 transactions across all time. Total sales of $642.7M significantly outpace purchases of $0, resulting in a net outflow of $642.7M. This selling activity appears largely discretionary, which may warrant closer attention from investors.